Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008; 14(1): 53-57
Corresponding Author of This Article
Professor Qin Ouyang, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. email@example.com
Article-Type of This Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jun-Ying Xiang, Qin Ouyang, Guo-Dong Li, Nan-Ping Xiao, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
ORCID number: $[AuthorORCIDs]
Correspondence to: Professor Qin Ouyang, Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China. firstname.lastname@example.org
Received: June 12, 2007 Revised: August 27, 2007 Published online: January 7, 2008
AIM: To investigate possibility and clinical application of fecal calprotectin in determining disease activity of ulcerative colitis (UC).
METHODS: The enzyme-linked immunosorbent assay (ELISA) was used to measure the concentrations of calprotectin in feces obtained from 66 patients with UC and 20 controls. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), acid glycoprotein (AGP) were also measured and were compared with calprotectin in determining disease activity of UC. The disease activity of UC was also determined by the Sutherland criteria.
RESULTS: The fecal calprotectin concentration in the patients with active UC was significantly higher than that in the inactive UC and in the controls (402.16 ± 48.0 &mgr;g/g vs 35.93 ± 3.39 &mgr;g/g, 11.5 ± 3.42 &mgr;g/g, P < 0.01). The fecal calprotectin concentration in the inactive UC group was significantly higher than that in the control group (P < 0.05). A significant difference was also found in the patients with active UC of mild, moderate and severe degrees. The area under the curve of the receiver operating characteristics (AUCROC) was 0.975, 0.740, 0.692 and 0.737 for fecal calprotectin, CRP, ESR and AGP, respectively. There was a strong correlation between the fecal calprotectin concentration and the endoscopic gradings for UC (r = 0.866, P < 0.001).
CONCLUSION: Calprotectin in the patient’s feces can reflect the disease activity of UC and can be used as a rational fecal marker for intestinal inflammation in clinical practice. This kind of marker is relatively precise, simple and noninvasive when compared with other commonly-used markers such as CRP, ESR and AGP.
Citation: Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008; 14(1): 53-57
Ulcerative colitis (UC) is a chronic, idiopathic inflammatory bowel disease characterized by remission of disease activity. The incidence and the prevalence rates of UC are increasing in China. It is important to accurately evaluate intestinal mucosa inflammation in the management of these patients, particularly for the assessment of therapeutic effectiveness. Colonoscopy and biopsy are useful in the assessment of intestinal mucosa inflammation of patients with UC, but these examinations can be a heavy burden to the patient. Clinical evaluations including laboratory tests such as C-reactive protein (CRP)[4–6], erythrocyte sedimentation rate (ESR), acid glycoprotein (AGP), and platelet count, have been used for the determination of disease activity of UC, but none of them are specific for gut inflammation. Therefore, a new marker that will be more sensitive and specific for determination of disease activity of UC is urgently needed in clinical practice.
An alternative approach to the assessment of the presence of intestinal inflammation is to analyze the whole gut lavage fluid or to quantitate the protease resistant neutrophil derived proteins such as lactoferrin in the patient’s feces, and this approach can be non-invasive for the patient. Calprotectin is one of these proteins. It is a major protein in the neutrophilic granulocytes and the macrophages, which accounts for 60% of the total protein in the cytosol fraction in these cells. This kind of protein can resist metabolic degradation caused by intestinal bacteria, and the protein is relatively stable in stools for up to one week at room temperature. It can differentiate between patients with organic or non-organic intestinal disease, and can be useful in detecting colorectal cancer and inflammatory disorders, and can also be useful in predicting a relapse of inflammatory bowel disease.
Our study was aimed at the measurement of the concentration of calprotectin in the feces of the UC patient and at the comparison of it with commonly-used markers in clinical practice, such as CRP, ESR and AGP.
MATERIALS AND METHODS
Sixty-six patients with UC (age, 38.97 ± 2.39 years) were enrolled in the study, including 15 patients with proctitis, 22 with left-sided colitis, and 29 with pancolitis. Of the patients, 44 were hospitalized. The patients’ disease activities were assessed according to the Sutherland criteria in which a score of more than two was considered to indicate the active stage of the disease. The control group consisted of 20 subjects (age, 38.95 ± 3.59 years) with no confirmed abnormality in the upper or lower digestive tract.
Methods of stool collection
The patients were instructed to defecate directly into a polystyrene container. The stool samples were stored at -70°C until the time of measurement.
Measurement of fecal calprotectin by ELISA
The stool samples were thawed, and 50-100 mg of the sample was suspended with 2500-5000 &mgr;L of the fecal extraction buffer, and was homogenized; then, the suspernatant was diluted to 1:50, and the calprotectin was analyzed by the enzyme-linked immunosorbent assay (ELISA) using the Nycotest Phical ELISA kit (Nycomed, Norway). Microcapture and immunoaffinity-purified rabbit anticalprotectin conjugated with alkaline phosphatase was used for the development. The ELISA read the absorbance at 405 nm for 96-well plates. The results of the sample tests were evaluated from the standard curves. CRP, ESR and AGP were measured in the clinical laboratory, West China Hospital, based on the instructions provided by the reagent manufacturer.
Statistical analysis was performed using the statistical package SPSS 11.5. The data were expressed as means ± SD. The Mann-Whitney test was used to assess differences in the laboratory parameters between the groups, and Spearmans’ correlation was used to analyze the correlation between the parameters. All the P values were two tailed; P values < 0.05 were considered statistically significant. The receiver operating characteristics (ROC) (sensitivity and specificity) were assessed by the curve analysis as described by Henderson.
Concentrations of fecal calprotectin, CRP, ESR and AGP in patients with UC and in controls
There was a significant difference in the fecal calprotectin concentration between the patients with active UC and the patients with inactive UC (P < 0.01) (Table 1, Figure 1). The calprotectin concentration was significantly greater in the patients with inactive UC than in the controls (P < 0.05). The patients with active UC had higher levels of CRP, ESR and AGP than the patients with inactive UC and the controls (P < 0.05), but there was no significant difference between the patients with inactive UC and the controls.
Table 1 Concentrations of fecal calprotectin, CRP, ESR and AGP in the UC patients and the controls (mean ± SD).
Figure 1 Concentrations of fecal calprotectin, CRP, ESR and AGP in the UC patients and the controls.
UC (A): Ulcerative colitis (active phase); UC (I): Ulcerative colitis (inactive phase). aP < 0.05 vs the control, bP < 0.01 vs UC (I) and the control, cP > 0.05 vs the control, eP < 0.05 vs UC (I) and the control.
Relationship between the concentrations of fecal calprotectin, CRP, ESR and AGP and the disease activity index (DAI) in UC
As shown in Figure 2, the concentrations of fecal calprotectin, CRP, ESR and AGP in UC had a good correlation with DAI. The correlation coefficients between DAI and the concentrations of fecal calprotectin, CRP, ESR and AGP were 0.866, 0.492, 0.433 and 0.533, respectively. This association was strongest for fecal calprotectin and weakest for ESR.
Figure 2 Concentrations of fecal calprotectin, CRP, ESR and AGP in UC and the DAI score of UC.
Specificity and sensitivity
The correspondence between the DAI-based classification of the active or the inactive disease status and the classification based on the parameter cut-offs was analyzed for each parameter (Table 2) and was expressed as the percentage of the samples that were correspondingly identified (specificity and sensitivity). Specificity was highest for fecal calprotectin, and lowest for AGP. The specificity rates for fecal calprotectin, CRP, ESR and AGP were 79.4%, 69.0%, 68.9% and 65.5%, respectively. The sensitivity for fecal calprotectin was relatively high, but was relatively low for CRP. The sensitivity rates for fecal calprotectin, CRP, ESR and AGP were 91.9%, 62.2%, 64.9%, and 67.6%, respectively. The ROC curves showed the trade-off between specificity and sensitivity for fecal calprotectin (the area under the curve, AUC, 0.975 ± 0.015; P < 0.001), for CRP (AUC, 0.740 ± 0.061; P < 0.001), for ESR (AUC, 0.692 ± 0.064; P < 0.01), and for AGP (AUC, 0.737 ± 0.062; P < 0.001) (Figure 3). The AUCROC of fecal calprotectin was greater than that of CRP, ESR or AGP (P < 0.01).
Table 2 Specificity and sensitivity for fecal calprotectin, CRP, ESR and AGP.
Figure 3 The ROC curve analysis on the abilities of calprotectin, CRP, ESR and AGP to make a difference between active UC and inactive UC.
Chronic relapsing and remitting inflammation of the gastrointestinal tract is the hallmark of UC. One of the most prominent histological features observed in UC is infiltration of the neutrophils into the inflamed mucosa at an early stage of inflammation. The neutrophils are major sources of inflammatory cytokines, chemokines proteases, active lipids, and reactive oxygen derivatives, as well as a full complement of factors needed to exacerbate mucosal inflammation and tissue injury[22–25] The fecal calprotectin excretion of indium-labeled autologous granulocytes has for a long time been suggested as the gold standard test in assessing bowel inflammation in inflammatory bowel disease. However, as it involves an exposure to radiation and prolonged fecal collection, which is unpopular with patients and laboratory staff, it is only used as a research tool. In patients with inflammatory bowel disease, a three day excretion of indium-labeled granulocytes correlated well with a daily excretion and a one-off fecal calprotectin level.
In this study, we focused on the evaluation of any relationship that might exist between the mucosal neutrophil infiltration represented by calprotectin, CRP, ESR, AGP and the UC disease activity represented by the Sutherland criteria. The DAI score of UC is the sum score of the following four parameters (each scoring between nought and three, making 12 the worst score): stool frequency, rectal bleeding, mucosa appearance, and physician’s global assessment. It reflects the clinical representation of UC and is the most extensive and simplest DAI. It is adopted by the guidelines for the management of inflammatory bowel disease in the fourth Asia Pacific Digestive Week. Our results showed that fecal calprotectin concentrations were significantly higher in the patients with active UC than in the patients with inactive UC and in the controls. In addition, our results showed that fecal calprotectin concentration was higher in the patients with inactive UC than in the controls. In the patients with UC, the fecal calprotectin concentration had a better correlation with DAI than the CRP, ESR or AGP concentration.
The ROC curve is adopted not only to ensure the right cut-off point, but also to compare the diagnostic values of two or more diagnostic tests. The ROC analysis on the fecal calprotectin concentrations under these circumstances, showed that a cut-off point of 50.0 &mgr;g/g for calprotectin had a 91.9% sensitivity and a 79.4% specificity for making a differentiation between active UC and inactive UC. These were significantly better than those obtained with CRP, ESR and AGP.
In this study, ELISA was used to determine the fecal calprotectin concentrations in the patients with UC and in the controls. In comparison to endoscopy this method is simple, noninvasive and inexpensive. However, fecal calprotectin can only reflect the excretion of neutrophils. Many infective diseases can cause a large number of neutrophils to infiltrate, so that fecal calprotectin is elevated in a number of organic gastroenterological disorders[29–31]. Therefore, fecal calprotectin is not desirable as a method that is required to differentiate efficiently between UC and infective colitis, so it cannot take the place of an endoscope in diagnosing UC. Regardless of how sensitive the calprotectin technique may be in the detection of disease activity in patients with previously diagnosed UC, its greater potential use is in identifying patients with UC and in differentiating between patients with UC and patients with non-inflammatory disorders, still requires further study.
In conclusion, the determination of fecal calprotectin is an objective approach to grading the mucosal disease activity in patients with inflammatory bowel disease. The advantages of fecal calprotectin are simplicity, noninvasiveness, and relatively low cost. Fecal calprotectin can be useful not only in research but also in clinical practice.
The incidence and the prevalence rates of ulcerative colitis (UC) are increasing in China. It is important to accurately evaluate intestinal mucosa inflammation in the management of these patients, particularly for the assessment of therapeutic effectiveness. No clinical evaluations are specific for gut inflammation. Therefore, a new marker that will be more sensitive and specific for determination of disease activity of UC is urgently needed in clinical practice.
Calprotectin can resist metabolic degradation caused by intestinal bacteria, and the protein is relatively stable in stools for up to one week at room temperature. Some foreign research has shown that fecal calprotectin concentrations were significantly higher in patients with active UC than in patients with inactive UC and in the controls.
Innovations and breakthroughs
Our study improved the originality of the manuscript assessing the relationship between calprotectin level and extension of colitis. This question was not described enough in the medical literature.
The aim of our study was to investigate the possibility and clinical application of fecal calprotectin in determining disease activity of UC. Our findings suggest that calprotectin in the patient’s feces can reflect disease activity of UC and can be used as a rational fecal marker for intestinal inflammation in clinical practice.
Receiver operating characteristics (ROC) curve is adopted not only to ensure the right cut-off point but also to compare the diagnostic values of two or more diagnostic tests. The accuracy of diagnostic test is characterized by the sensitivity and specificity. A ROC curve displays the sensitivity of a diagnostic test over all possible false-positive rates.
This manuscript provided compelling evidence that fecal calprotectin was a better marker than C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or acid glycoprotein (AGP) and improved the originality of the manuscript assessing the relationship between calprotectin level and extension of colitis. It deserves to be published.
S- Editor Liu Y L- Editor Roberts SE E- Editor Li HY
Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China.World J Gastroenterol. 2002;8:158-161.
Carpenter HA, Talley NJ. The importance of clinicopathological correlation in the diagnosis of inflammatory conditions of the colon: histological patterns with clinical implications.Am J Gastroenterol. 2000;95:878-896.
Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Lofberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis.Gut. 2000;47:404-409.
Poullis AP, Zar S, Sundaram KK, Moodie SJ, Risley P, Theodossi A, Mendall MA. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders.Eur J Gastroenterol Hepatol. 2002;14:409-412.
Dunker MS, Ten Hove T, Bemelman WA, Slors JF, Gouma DJ, Van Deventer SJ. Interleukin-6, C-reactive protein, and expression of human leukocyte antigen-DR on peripheral blood mononuclear cells in patients after laparoscopic vs conventional bowel resection: a randomized study.Dis Colon Rectum. 2003;46:1238-1244.
Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease.Inflamm Bowel Dis. 2004;10:661-665.
Sachar DB, Smith H, Chan S, Cohen LB, Lichtiger S, Messer J. Erythrocytic sedimentation rate as a measure of clinical activity in inflammatory bowel disease.J Clin Gastroenterol. 1986;8:651-654.
Lubega J, Davies TJ. A comparison of serum mucoprotein with serum alpha 2 acid glycolprotein, haptoglobin, and alpha 1 antitrpsin assays in monitoring inflammatory bowel disease.Clin Chim Acta. 1990;188:59-69.
van Wersch JW, Houben P, Rijken J. Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease.J Clin Chem Clin Biochem. 1990;28:513-517.
Larsen TB, Nielsen JN, Fredholm L, Lund ED, Brandslund I, Munkholm P, Hey H. Platelets and anticoagulant capacity in patients with inflammatory bowel disease.Pathophysiol Haemost Thromb. 2002;32:92-96.
Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study.Gastroenterology. 1976;70:439-444.
Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonal TT. Tumor necrosis factor alpha in stool as a marker of intestinal inflammtation.Lancet. 1992;339:89-91.
Uchida K, Matsuse R, Tomita S, Suqi K, Saitoh O, Ohshiba S. Immunochemical detection of human lactoferrin in feces as a new marker of inflammatory gastrointestinal disorders and colon cancer.Clin Biochem. 1994;27:259-264.
Kayazawa M, Saitoh O, Kojima K, Nakgawa K, Tanaka S, Matsuse R, Uchida K, Hoshimoto M, Hirata I, Katsu K. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.Am J Gastroenterol. 2002;97:360-369.
Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin.Am J Clin Pathol. 1985;84:24-34.
Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, Roald B. Faecal calprotectin: A novel test for the diagnosis of colorectal cancer?Scand J Gastroenterol. 1993;28:1073-1076.
Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I. Functional and clinical aspects of the myelomonocyte protein calprotectin.Mol Pathol. 1997;50:113-123.
Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating calprotectin in feces. A methodologic study.Scand J Gastroenterol. 1992;27:793-798.
Tibble JA, Sigthorsson G, Bridger S, Fagerthol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.Gastroenterology. 2000;119:15-22.
Gionchetti P, Arienzo A, Rizzello F, Manguso F, Maieron R, Lecis PE, Valpiani D, Iaquinto G, Annese V, Balzano A. Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial.J Clin Gastroenterol. 2005;39:291-297.
Henderson AR. Assessing test accuracy on its clinical consequence: a primer for receiver operating characteristic curve analysis.Ann Clin Biochem. 1993;30:521-539.
Grisham MB, Yamada T. Neutrophils, nitrogen oxides and inflammatory bowel disease.Ann N Y Acad Sci. 1992;664:103-115.
Cassatella MA. The production of cytokines by polymor-phonuclear neutrophils.Immunol Today. 1995;16:21-26.
Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased secretion of proinflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin-10 during intestinal inflammation.Gut. 1998;42:470-476.
Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease.Gastroenterology. 1984;86:453-460.
Roseth AG, Schmidt PN, Fagerhol NK. Correlation between fecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein in patients with inflammatory bowel dieseases.Scand J Gastroenterol. 1999;34:50-54.
Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, Befrits R, Midhagen G, Rademaker J, Foldager M. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.Gut. 2005;54:960-965.
Ouyang Q, Tandon R, Goh KL, Ooi CJ, Oqata H, Fiocchi C. The emergence of inflammatory bowel disease in the Asian Pacific region.Curr Opin Gastroenterol. 2005;12:408-413.
Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology.J Gastroenterol Hepatol. 2003;18:756-762.
Larsen A, Hovdenak N, Karlsdottir A, Wentzl-Larsen T, Dahl O, Fagerhol MK. Faecal calprotectin and lactoferrin as markers of acute radiation proctitis: a pilot study of eight stool markers.Scand J Gastroenterol. 2004;30:1113-1118.
Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms.Acta Paediatr. 2005;94:1855-1858.